All Oncology News

Oral Rinse-Based Test Demonstrates Ability to Detect Recurrence of Head and Neck Cancer

R. Lor Randall, MD, FACS, highlights key findings from the pivotal MOTION trial of vimseltinib in patients with TGCT.

Elizabeth J. Franzmann, MD, FACS, of Sylvester Comprehensive Cancer Center

Kyle Doherty

Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

Radhika Bansal, MBBS, postdoctoral fellow, Mayo Clinic

Courtney Flaherty

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

Marina Chiara Garassino, MD, from the University of Chicago

Silas Inman

Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Triparna Sen, PhD

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Patrick Forde, MBBCH, of Johns Hopkins Medicine

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Tina Cascone, MD, PhD, of MD Anderson Cancer Center

Megan Hollasch

Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital

Caroline Seymour

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Matthew Smeltzer, PhD, of The University of Memphis

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Christopher A. Yasenchak, MD, of of Willamette Valley Cancer Institute and Research Center/US Oncology Research

Kristi Rosa

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Jason R. Westin, MD, of The University of Texas MD Anderson Cancer Center

Gina Mauro

The OncFive: Top Oncology Articles for the Week of 9/1

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

OncLive Staff

Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Neha Mehta-Shah, MD, MSCI, assistant professor, Washington University

Tony Berberabe, MPH

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Non-Hodgkin Lymphoma | Image Credit: © freshidea - stock.adobe.com

Ariana Pelosci

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Russ Conroy

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chris Ryan

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

Meletios A. Dimopoulos, MD, professor, chairman, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine

Chris Ryan

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

Leonard Mazur, CEO, Citius Pharma, Citius Oncology

Caroline Seymour

New Research Offers Hope for Safer and More Effective Blood Stem Cell Transplants

The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.

Dana-Farber Cancer Institute

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Tony Berberabe, MPH

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Kristi Rosa

Vorasidenib Breaks Through as the First Systemic Therapy for Select Patients With Glioma

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Ashling Wahner

Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Caroline Seymour

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

Kristi Rosa

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

ABD-147 has received orphan drug designation from the FDA for use in patients with neuroendocrine carcinoma.

Pyrotinib Plus Metronomic Vinorelbine in HER2+ Advanced Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

Chris Ryan

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Tony Berberabe, MPH